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INTRODUCTION
Critically ill patients often experience stress-induced hyperglycaemia and high insulin resistance, even with no prior diabetes [1] [2] [3] [4] . The increased counter-regulatory hormone and cytokine response stimulates endogenous glucose production and increases effective insulin resistance. Absolute and relative insulin deficiency, and drug and steroid use are further causes. Studies also indicate that high glucose content nutritional support regimes result in excess glucose [5] [6] [7] . More recently, reductions in enteral nutrition [8] , and the use of dextrose as a diluent in intravenous medication [9] , resulted in reductions in glycaemia, and the alleviation of the counterregulatory response [3, 4, 10, 11] .
Although hyperglycaemia can be a marker of severity of illness, it also worsens outcomes, leading to an increased risk of further complications such as severe infection [12] , myocardial infarction [1] , and critical illnesses such as polyneuropathy and multiple-organ failure [2] . There is also evidence of significant reductions in need for dialysis, bacteremia and number of blood transfusions with aggressive blood glucose control [13] . van den Berghe [2, 14] showed that tight glucose control to less than 6.1mmol/L reduced cardiac ICU patient mortality by up to 45% while Krinsley [15, 16] showed a 17-29% total reduction in mortality over a wider ICU population with a higher glucose limit of 7.75mmol/L. Short-term, adaptive model-based protocols for insulin-mediated glucose control have been developed utilising integral-based identification of time-varying patient specific parameters [17, 18] . These insulin-based protocols are suited for clinical use, but have limitations. More specifically, high effective insulin resistance due to stress of condition and increased counter-regulatory dynamics can result in hyperglycaemia regardless of hyperinsulinaemia [17, 18] . Metabolic clearance rate is not stimulated with hyperinsulinaemia under conditions of stress, as endogenous glucose production is, which compounds hyperglycaemia [19, 20] . Insulin effect can also saturate at the supraphysiological insulin concentrations that exist under aggressive insulin therapy [18, [21] [22] [23] [24] [25] , limiting the achievable glycaemic reduction using insulin alone if effective insulin resistance is high.
As a result, exogenous nutritional inputs must be reduced to effect a reduction in hyperglycaemia. In critical care, research by Patino et al. [5] with lower glucose nutrition alone has seen significant reductions in average blood glucose levels.
Additionally, Patino et al. found poorer clinical outcome of hyperdynamic cardiorespiratory repercussion, high CO 2 production, and hepatic steatosis with high caloric loads, and no suppression of excessive endogenous glucose production with hypercaloric TPN. Hence, reduced glucose nutrition combined with insulin administration can act to control both sides (input and removal) of the glucose balance.
This paper develops and presents a pilot study of a long-term controller for safe regulation of glycaemia under elevated insulin resistance and glucose intolerance in critically ill patients by modulating enteral nutrition inputs in addition to conventional basal-bolus intravenous insulin therapy. Clinical proof-of-concept pilot trials of the algorithm are performed which show the algorithm adaptability to time-varying intraas well as inter-patient variability in condition while requiring relatively infrequent glucose measurement. This research is a step towards randomized, comparative cohort studies of clinical outcomes using the developed protocol.
Previous blood glucose control research includes controlled experiments in insulin infusion by Hovorka et al. [26] , Chee et al. [27] , and Chase et al. [18, 28] . Adaptive bolus-based control using insulin-alone by Chase et al. [18] , is the basis of this work.
The primary difference in this research is the improvement in control under elevated insulin resistance by modulation of nutritional support in addition to insulin input.
METHODS
System model
Tight blood glucose control requires a patient-specific glucose-insulin regulatory system model that captures the fundamental dynamics. Chase et al. [17, 18] used an extended system model that captured rate of insulin utilisation, insulin losses and saturation dynamics, and is also used in this study:
The [17, 18] .
For this study, k, n, α G , α I and V were initially set to generic population values [18, 29] . During the clinical trials, k, α G and V were tuned to match patient dynamics while the glucose distribution volume was taken as 0.19L/kg of the patient total body mass [30] [31] [32] . The parameters n and α I were set to 0.16min -1 and 0.0017L/mU [18] , which is consistent across many studies e.g. [33] [34] [35] [36] . The parameter α G = 1/65L/mU is an initial conservative choice for likelier underestimation of saturation [18, 21, 37] while k was set to 0.0198min -1 for an effective insulin half-life of 35min in the interstitial sites [18] .
In Equation (1), G E represents the patient-specific equilibrium state under constant feed, insulin infusion, insulin sensitivity and glucose clearance. Due to ongoing exogenous insulin infusion and variable nutritional inputs, an instantaneous equilibrium blood glucose level can be difficult to determine [17] . Hence, the current glucose value is used to update G E every two hours after a feed rate modulation. Equation (3) does not include endogenous insulin or glucose production. Critically ill patients are also often hyperinsulinaemic. Although endogenous insulin production rate is fairly consistent across the non-critically ill population [35, [38] [39] [40] , its value can be highly variable and difficult to obtain quickly in critical care. However, endogenous insulin production is suppressed with significant exogenous insulin administration [32, 35, 41] . In addition, endogenous glucose production is known to be unsuppressed by insulin or glycaemia under conditions of stress [19, 20] . Hence, in this study, an unknown glucose supply is assumed and its effect is lumped in the time-varying parameter, p G while endogenous insulin production is assumed to be suppressed to a steady constant value under significant exogenous insulin input. Any deviation from these assumptions will result in a scaling in the values of S I , if p G is held constant, and the effect on control should be minimal.
Variable enteral nutrition model
Chase et al. [18] modelled the constant enteral feed rate in their trials, P(t), as a constant value. In this study, stepwise enteral mixed meal glucose fluxes are employed for control and modelled using exponential functions.
where k pr and k pd (1/min) are the effective half lives of glucose transport from gut to plasma for both increasing (k pr ) and decreasing (k pd ) feed rates respectively, and i P and 1 + i P are the steps in enteral glucose feed rates.
Many studies have investigated glucose kinetics under non-steady conditions using tracers. Postprandial glucose kinetics are characterised by suppression of hepatic glucose output in both an oral glucose load (OGL) and continuous feeding approach [30, 42, 43] . Glucose disposal rate is largely unaffected [30, 42, 44] . Time periods for glucose absorption range from 120 to 240min [43] [44] [45] [46] for an OGL with a peak in total glucose at ~40mins [43] . Slower absorption was evidenced in a mixed meal formulation [47] , and [30] showed that mixed-meal postprandial GRa increased progressively until near steady-state between 230 and 270 minutes.
Oral glucose undergoes rapid intestinal absorption and a high percentage passes through the liver to appear systemically, sustaining a low first-pass splanchnic uptake [43] . Whether such dynamics are applicable to non-steady-state enteral glucose infusions where variations in glucose load are much smaller is unknown, although [43] showed no discernible difference in systemic oral glucose appearances with a half-sized oral glucose load. Any incretin effect present is likely to be minimal as enteral feeds are administered long-term and are held in steady state for at least 2 h before the commencement of the trial.
Model-based methods of calculating glucose fluxes [43, 48, 49] using tracer concentrations are limiting and unsuitable for real-time clinical application. Hence, different exponential rates for total GRa rise (k pr ) and decay (k pd ) can be used to model transient hepatic glucose output and first-pass splanchnic uptake in non-steady feeding. Impaired uptake of glucose in diabetes and stress-induced hyperglycaemia [30, 42, [50] [51] [52] [53] imply a slow decay rate in total GRa following nutritional feed reduction. Conversely, rapid intestinal absorption implies a rapid rise rate in total GRa [43] . Therefore, the values of k pr and k pd are set to 0.0347min -1 and 0.0068min -1 from data in the literature, corresponding to half-lives of 20 and 100mins. Figure 1 shows the modelled total nutritional input, P(t), following enteral feed rate variations using k pr = 0.0347min -1 and k pd = 0.0068min -1 . Note that this model is only designed to capture the first order dynamics of glucose appearance as a function of enteral feed.
Hence Equations (4)- (5) effectively assumes a linear 2-compartment model.
While the digestion process prior to absorption is highly variable, such variability is minimised by several means. Firstly, the mixed meal formulation is standardised.
Also, an exclusion criterion of abnormal gastric emptying rates as determined from residual gastric aspirates (Section 3.1 Patient Cohort) is placed on prospective patients for the study. Lastly, enteral feed fluxes are calculated based on the rapidly absorbed glucose caloric content, not protein-and fat-derived calories. These steps reinforce the presumption that only the glucose is absorbed in the first-pass into plasma even though the protein and fat content contribute to the gluconeogenic input into plasma at some later time. Note also that the 2-compartment model mimics many standard mixed meal models used [54] in analysing diabetic responses.
Parameter fitting and prediction
Prior to resolving a bolus size and feed rate to achieve a target, S I must be fitted. The parameter fitting is described in [17, 18] . The main difference is the assumption of p G = 0.01, a value found in [17] to be relatively constant and insensitive across a diverse ICU patient cohort. The fitted insulin sensitivity, S I , is used to predict the blood glucose response in the following hour. The insulin sensitivity in the following hour The required combination of bolus size, insulin infusion rate and/or nutritional feed rate to achieve the target glucose level is determined iteratively using the estimated S I 
S , and Equations (1)- (3) . Delta functions are used to model insulin boluses, u ex (t), when solving Equations (1)- (3) with the duration of a bolus set to 1 minute.
Similarly, Equation (4) is used to determine P(t) based on the step changes in nutritional input rate.
CLINICAL TRIAL METHODOLOGY
Patient cohort
All patients were fed enterally only with the mixed-meal formulation RESOURCE™ The proof of concept clinical trial patient cohort (n = 7) was selected from the Christchurch ICU intensive care population. This subset represents a heterogeneous cross-section of ICU population, in APACHE and SAP score, age, sex and mortality (see Table 1 ). The high proportion of septic patients stems from their severity of condition and hence, likelihood of hyperglycaemia. APACHE and SAP scores are calculated from the time at which patient condition is at its worst during the first 24
hours of ICU stay. The mean age is 65.4 ± 8.1 years (mean ± SD), and five out of seven patients are male. These statistics are comparable over this small cohort to other ICUs [2, 55] and an earlier Christchurch ICU study [29] . The ICU survival was obtained subsequently from patient records.
Clinical trial procedure
The proof-of-concept clinical trials span 10h, from 0900h to 1900h. The pre-trial period begins at 0600h, at which time the insulin infusion and feed rate are kept constant. The pre-trial period is necessary to obtain an estimate of the patients' onboard insulin level and equilibrium blood glucose, G E . At 0900h, the clinical trial begins and the feed rate is decreased by 30-40% depending on current glucose level and feed rate. Blood glucose is measured at 15min intervals until 1000h. Paired capillary blood samples are taken via finger-prick using lancets and analysed using a bedside Glucocard™ Test Strip II glucose testing kit (Arkray Inc., Kyoto, Japan). In some cases, arterial blood samples were used when finger pricking was unavailable.
At the end of the first hour, S I is fitted to the first hour of data. Using Equation (6), S I is predicted for the next hour. A target is set for a 10-15% reduction in current glucose level to a minimum of 5mmol/L. A combination of insulin bolus size, insulin infusion rate, and enteral feed rate is then resolved to achieve the target at the end of the next hour. Blood glucose is monitored every 30mins, and S I is re-evaluated every hour using the prior hours' data. Following each re-evaluation, the controller determines the required combination of control inputs to achieve the new target depending on insulin resistance and estimated insulin saturation level [18] .
Hence, the overall approach is target-driven and incorporates real-time optimisation of insulin sensitivity for adaptive control. The overall clinical trial procedure is outlined in Figure 3 . A limit of 6U is placed on the total insulin prescribed per hour.
In addition, a 30mU/L cap was placed on the estimated ineffective insulin, defined by 
CLINICAL TRIAL RESULTS AND DISCUSSION
This section presents the results of the proof-of-concept clinical trial tests of the variable feed and insulin control protocol developed.
Trial 1
Patient 1 was a 56-year-old male, Type II diabetic with tetraplegia admitted into intensive care with pneumonia and sepsis. It was his second visit to the ICU and 22 nd day of stay. His equilibrium blood glucose level was 12.1mmol/L at the start and 11.2mmol/L three hours prior. The assumed values of k, k pd and k pr resulted in a smooth fitted S I without further adaptation. The trial progression and modelled patient dynamics are shown in Figure 4 and Table 2 .
The insulin distribution volume, V = 12L, was found to match patient dynamics, and the glucose distribution volume for calculating P(t) was adequately assumed as 0.19L/kg body mass (~15L). The insulin sensitivity remained reasonably constant throughout the first 360mins of the trial, which resulted in hourly-target acquisition with less than 1mmol/L absolute error.
Referring to Figure 11 , the infusion was varied from 3.0-1.0U/hr and supplemented with three 3.0U boluses. The feed rate was reduced from 700-280kcal/day of glucose (1944-778kcal/day total calories) in the first two hours, which was then maintained until trial completion. After 360mins, the insulin sensitivity began to rise steadily, which affected the accuracy of target acquisition. The last four targets were consistently overestimated, although by not more than 1.0mmol/L, which was the result of the gradual increase in insulin sensitivity. Note also that the large percentage error is partly due to the much lower than average glucose values.
The gradual increase in identified insulin sensitivity coincided with improved conscious level that may have reflected improved glucose metabolism and increased hepatic glucose uptake, resulting in increased effective insulin sensitivity as seen by the controller. The reduction in blood glucose achieved was 70.2% from the initial hyperglycaemic 12.1mmol/L.
Trial 2
Patient 2 was a 64-year-old male, admitted into intensive care post-operatively following cardiac surgery. He has sepsis and acute renal failure. At the time of the trial, it was his 6 th day of stay. The trial progression and control inputs are shown in Figure 5 and 11, and Table 2 .
As shown in Figure 11 , the feed rate was reduced from the 700-420kcal/day of glucose (1944-1167kcal/day total calories) in the first hour, but was increased back to 670kcal/day of glucose (1861kcal/day total calories) at 120mins to counter the rate of decrease in glucose level. Subsequent feed rate reductions were prescribed at 180mins to 520kcal/day of glucose (1444kcal/day total calories) and at 240mins to the 280kcal/day of glucose minimum (778kcal/day total calories), which was held until trial completion due to the highly insulin resistant nature of the patient, in that period.
Trial 2 highlights some of the difficulties in ICU glycaemic control. From 0 to 120mins, a steady and significant reduction in glucose level was observed stemming from the initial feed rate reduction at 0mins. At 150mins, the glucose measurement was on course for the 180min target of 5mmol/L. However, at 180mins the measurement was 8.5mmol/L, which is most likely due to a sudden hyperadrenergic event the patient suffered around that time. The patient suffered a hyperdynamic cardiovascular reaction i.e. atrial fibrillation. This episode highlights how the stress of condition (manifested here in high cardiac output) in the critically ill promotes the counter-regulatory response and sudden changes in glucose level. From that point, the patients' insulin requirement changed with increased effective insulin resistance, requiring much larger insulin boluses after 180mins. Hence, the controller was able to adapt to this significant change in condition and metabolic status that is not atypical in critical care.
Although three targets were missed, the model simulation was tracking the blood glucose measurements accurately within the next hour and the target at 300mins was achieved with 5.1% error. Target acquisition was accurately maintained for the remainder of the trial as the insulin sensitivity remained reasonably constant, albeit relatively low, resulting in a less than 1mmol/L absolute target error. Due to the low fitted insulin sensitivity, large feed rate reductions and insulin boluses were required to achieve good control compared to the initial 60-120mins.
The total reduction in blood glucose achieved was 25.3% from the initial moderately 
Trial 3
Patient 3 was a 60-year old male, admitted to the ICU seven days before the trial. He was admitted post-operatively following cardiac surgery with ARDS and multiple organ failure, requiring some dialysis. The equilibrium glucose level at the start of the trial was 8.7mmol/L and 9.1mmol/L one hour beforehand. All parameters were standard values except k, which was changed by the controller to 0.0277min -1 corresponding to a t 1/2 = 25mins. This change reduces modelled losses (n-k) thus matching the patients' renal failure condition where the kidneys do not remove as much insulin. The trial progression and control inputs administered are shown in Figure 6 and 11, and Table 2 .
The control algorithm prescribed a feed rate cut from 545-318kcal/day of glucose (1514-883kcal/day total calories) in the first 120mins but eventually increased the feed rate back to 545kcal/day of glucose (1514kcal/day total calories) at 240mins For the first 5 hours, the glucose level was maintained in the desired 4-6mmol/L band.
However, a sudden shift in patient condition occurred at 300mins. Note that up until that point, no insulin boluses had been administered, the insulin infusion was a constant 2U/hr since the start of the trial, and only small feed rate changes had been The mean target error was 9.9% (range, [0.2, 33.0] %) with a maximum absolute error of 1.65mmol/L. Neglecting the few errors arising from the rapid increase in insulin sensitivity, the mean error reduces to 5.0%. The fitted insulin sensitivity distribution remained relatively constant, which contributed to the high rate of successful target acquisition. Overall, the errors were very low and all targets were met.
Trial 5
Patient 5 was a 73-year old, insulin dependent Type II diabetic male admitted into ICU with aspiration pneumonia secondary to mediastinal sepsis and an oesophagectomy. The patient had spent 29 days in ICU, and the equilibrium glucose level at the start of the trial period was 6.8mmol/L, although he had significantly elevated blood glucose levels (9-10mmol/L) earlier. With near normal initial blood glucose, the controller would again be trialled in maintaining tight control throughout the 10-hour trial period. The results are shown in Figure 8 and 11, and Table 2 .
The resulting fitted insulin sensitivity was very smooth with only minor discontinuities between each fit. The insulin infusion was kept constant throughout the trial at the initial value of 1.5U/hr, except for a one hour period, and supplemented with six boluses of 0.5-1.5U. The feed rate was reduced from 550-365kcal/day of glucose (1528-1014kcal/day total calories) for the first four hours and increased back to 464kcal/day of glucose (1289kcal/day total calories) by the end of the trial. For the first 5 hours, the blood glucose was reduced and then held at 5mmol/L.
The rise in blood glucose between 300mins and 480mins was caused by a miscommunication. The control input at 300mins as determined by the controller was to maintain the insulin infusion at 1.5U/hr and administer a 0.6U insulin bolus, but was misconstrued by the attending nurse as reduce the insulin infusion to 0.6U/hr only. The resultant increase in blood glucose was halted at 420mins into the trial when the controller was given the correct values. Even so, the controller predicted the rise in glucose accurately when the data was updated.
The reduction in blood glucose achieved was 30.1% from the initial mild hyperglycaemia of 6.8mmol/L to a final value of 4.75mmol/L. The mean target error was 2.3% (range: 0-5%) and a maximum absolute error of 0.25mmol/L was recorded.
The insulin sensitivity distribution for the whole trial remained relatively constant, which contributed to the high rate of successful target acquisition. Overall, the errors were very low and all targets were met.
Trial 6
Patient 6 was a 57-year old male admitted into the ICU with pneumococcal meningitis. He also suffered a stroke, arising from his inflammatory condition. He had spent 6 days in ICU. His equilibrium glucose level at the start of the trial period was 7.5mmol/L, and 7.0mmol/L at the start of the 3-hour pre-trial period. The results are shown in Figure 9 and 11, and Table 2 .
The resulting fitted insulin sensitivity was very smooth with only minor discontinuities between each fit. At 120mins, the enteral feed was disconnected in anticipation of the patient being transferred for an immediate MRI scan as requested by the attending physician. The insulin infusion was unchanged at the initial 2U/hr.
At 180mins, the trial was interrupted and the insulin infusion was disconnected. At 318mins, the patient was returned and the insulin infusion and enteral feed restarted at a rate of 0.5U/hr and 280kcal/day, respectively. These values were maintained until the end of the trial.
One unpaired glucose measurement was obtained at 270mins while the patient was undergoing the MRI scan. From the model simulation, it is likely that this measurement was inaccurate given that the target at 300mins was within the model simulation. Before the scan, two insulin boluses of 1.1 and 2.0U with a constant 2U/hr infusion achieved a reduction in glucose level to 5.7mmol/L with the initial 827-545kcal/day of glucose (2297-1514kcal/day total calories) feed rate cut at 0mins.
After the scan, the patient became noticeably more insulin resistant, as shown by the insulin sensitivity plot. The feed rate was reduced to its minimum level of 280kcal/day of glucose (778kcal/day total calories) and bolus size was increased up to 5.5U. In the last five hours of the trial, the average insulin administered was 5.0U/hr compared to 1.8U/hr in the first five hours.
The reduction in blood glucose achieved was 30.7% from the initial mild hyperglycaemia of 7.5mmol/L to a final value of 5.2mmol/L. With moderate insulin sensitivity, the glucose level was reduced and maintained in the 4-6mmol/L target band with a combination of insulin and feed rate reduction.
The mean target error was 7.6% (range, [1.3, 15 .0] %) with a maximum absolute error of 0.75mmol/L. The reduction in insulin sensitivity observed after the MRI scan may have resulted from transient increases in carbon dioxide when the patient was ventilated using a basic transport ventilator. However, the insulin sensitivity distribution for the whole trial remained relatively constant, which contributed to the high rate of successful target acquisition.
Trial 7
Patient 7 was a 73-year old female admitted into the ICU with an incarcerated hernia, acute renal failure and metabolic acidosis. The patient had spent 3 days in ICU, and the equilibrium glucose level at the start of the trial period was 9.9mmol/L, and 10.3mmol/L at the start of the pre-trial period. The results are shown in Figure 10 and 11, and Table 2 .
The resulting fitted insulin sensitivity was very smooth with only minor discontinuities between each fit. Initially, the effective insulin sensitivity was low, but at 240mins it began to gradually increase, reducing the average total insulin required per hour. The enteral feed rate was reduced from the initial 545kcal/day of to 318kcal/day of glucose at 0mins (1514-883kcal/day total calories) and was maintained until the end of the trial.
As a result of the increase in fitted insulin sensitivity, at 420mins the 5mmol/L target 
Control method and target acquisition error analysis
The overall mean target error for all trials was 8.9% (0.51mmol/L), with an absolute range of [0, 2.9] mmol/L. The Glucocard™ Test Strip II bedside glucose monitoring sensor is capable of obtaining 50% and 98% of measurements within ±5% and ±20%
error respectively, over typical glucose ranges [58] . Across the 7 clinical trials, 43%
of the targets were achieved within ±5% with a mean target error of 2.3%
(0.15mmol/L). Mean target error for errors >5% was 13.8% (0.79mmol/L). Out of the 63 targets, only six had errors larger than 20%, so that 91% of all measurements were within ±20% of targets. However, all of these errors can be explained by significant, rapid changes in patient condition, rather than pure measurement errors.
The target errors obtained are thus consistent with, and explainable, by published measurement errors from literature. 
where n = 63 and is the bootstrap sample size (9 targets for each of the 7 trials), i y is the achieved glucose value recorded for the ith target glucose value, i x , and i y ) is the value of the least squares linear regression curve at the target glucose value, i x .
The number of bootstrap samples was 4000. Figure 12 also shows the 95% confidence limits for the prediction of the achieved glucose values for a given target
value. The few glucose data points achieved with high accuracy at glucose concentrations >7mmol/L resulted in a very small effective variation in the bootstrap estimate. Conversely, the number of outliers from rapid changes in patient condition from the greater number of data points around normal glucose levels resulted in a larger variation in the bootstrap estimate. This result explains the confidence bands, which are nearly of equal width across the glucose range shown.
Note that this analysis is necessarily conservative, as outliers from rapid changes in patient condition were included. The non-parametric bootstrap confidence intervals point to a slight bias towards overshooting the target glucose concentration, which may be deemed safer in a clinical environment. However, this result cannot be confirmed with the current sample size (n = 63). A white residual plot based on the linear regression curve showed no systematic error in the model and methods as shown in Figure 13 . A correlation coefficient, R, between 0.7820 and 0.9216 can be stated with 95% confidence. A larger data point sample size from ongoing trials will confirm whether current target errors are within reported sensor parameters or partly due to other systematic problems.
Finally, it is also important to note the affect of patient cohort, and in particular level of illness as measured by APACHE II score, on the results. Overall, the clinical results showed tight control to less than 6.1mmol/L for a cohort with median APACHE II score of 23 (range, [17, 31] ). In comparison, van den Berghe et al [2] achieved similarly tight control with median APACHE II score of 9 (inter-quartile range, [7, 13] ), which represents a much lower level of illness. For a more comparable ICU population, Krinsley [13, 14] showed tight control to a higher 7.75mmol/L for a cohort with median APACHE II of 16 (inter-quartile range, [10, 23] ). However, both these studies used insulin alone to control glucose levels.
Hence, the significantly added control obtained by modulating nutrition, as well as insulin, to control glycaemic levels is seen in the ability to achieve tight control to a level similar to [2] for a more critically ill ICU cohort.
CONCLUSIONS
The clinical pilot trials conducted during this study demonstrated the potential of a control algorithm modulating both insulin and nutritional feed rate to accurately reduce and tightly regulate glucose levels despite significant inter-patient variability 
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